<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Endomyocardial fibrosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Endomyocardial fibrosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Endomyocardial fibrosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rebecca Cogswell, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nelson B Schiller, MD, FACC, FRCP, FASE</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Harry Acquatella, MD, FACC, FAHA</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 04, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Endomyocardial fibrosis (EMF) is a disease of rural poverty that is characterized by fibrosis of the apical endocardium of the right ventricle (RV), left ventricle (LV), or both. The clinical manifestations are largely related to the consequences of restrictive ventricular filling, including left and right sided heart failure (HF).</p><p>EMF refers to a specific syndrome with characteristic epidemiologic features. The epidemiology, pathophysiology, clinical manifestations, diagnosis, and treatment of EMF are reviewed here. Other cardiomyopathy syndromes with similar pathologies, including hypereosinophilia and/or fibrotic changes of the endocardium are addressed separately. (See  <a class="medical medical_review" href="/z/d/html/8135.html" rel="external">"Carcinoid heart disease"</a> and  <a class="medical medical_review" href="/z/d/html/2211.html" rel="external">"Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis", section on 'Cardiac disease'</a> and  <a class="medical medical_review" href="/z/d/html/4935.html" rel="external">"Treatment and prognosis of myocarditis in adults", section on 'Eosinophilic myocarditis'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Although accurate epidemiologic data are lacking [<a href="#rid1">1,2</a>], EMF is estimated to be the most common form of restrictive cardiomyopathy worldwide.</p><p>Most studies of EMF have been conducted in tropical regions where there is a high prevalence of disease such as Uganda [<a href="#rid3">3</a>], Nigeria [<a href="#rid4">4</a>], Ivory Coast, south India [<a href="#rid5">5</a>], Venezuela [<a href="#rid6">6</a>], and Brazil (<a class="graphic graphic_figure graphicRef126374" href="/z/d/graphic/126374.html" rel="external">figure 1</a>) [<a href="#rid7">7</a>]. Advanced disease has been described primarily in poor rural areas from several countries of eastern Africa (including Mozambique and Uganda). Endomyocardial fibrosis (EMF) was first recognized in Uganda during the 1940s and accounts for as much as 20 percent of cardiac cases sent for echocardiography in that country in contemporary series [<a href="#rid1">1,2,8</a>]. An echocardiographic screening study in Mozambique found a population prevalence of 20 percent; however, this study included patients with early, subclinical disease [<a href="#rid9">9</a>]. EMF also occurs in subtropical regions. Within endemic countries, there appears to be a regional variation [<a href="#rid10">10,11</a>]. </p><p>EMF is primarily a disease of the young, occurring in children, adolescents, and young adults. In Uganda, a bimodal peak at ages 10 and 30 has been observed [<a href="#rid12">12</a>], and a similar pattern was found in Mozambique [<a href="#rid9">9</a>]. The differences between genders in the frequency of disease have been variable [<a href="#rid9">9,12,13</a>]. </p><p class="headingAnchor" id="H1706592742"><span class="h1">PATHOLOGY</span><span class="headingEndMark"> — </span>In EMF, there is fibrosis of the right and/or left apical endocardial surfaces that leads to restrictive physiology [<a href="#rid14">14</a>]. Additionally, tethering of the atrioventricular (AV) valve papillary muscles and/or fibrosis of the respective ventricular inflow tracts leads to significant AV valve regurgitation. Gross pathology reveals ventricular endocardial thickening and fibrosis often with overlying thrombus. The atrium of the affected ventricle is often dramatically enlarged (<a class="graphic graphic_diagnosticimage graphicRef53361" href="/z/d/graphic/53361.html" rel="external">image 1</a>) with reduced ventricular volumes. Histopathology demonstrates increased type I collagen deposition, subendocardial infarction, fibrosis, and thrombus [<a href="#rid11">11,15</a>]. In many pathology studies, there is a lack of inflammation or eosinophilia, implying that at end-stage disease, the inflammatory process is inactive [<a href="#rid16">16</a>]. </p><p class="headingAnchor" id="H15162936"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>The cause of the underlying fibrotic process of endomyocardial fibrosis (EMF) is largely unknown; however, several theories exist and are briefly reviewed.</p><p class="headingAnchor" id="H15162944"><span class="h2">Eosinophilia</span><span class="headingEndMark"> — </span>Eosinophilia is the most commonly cited etiologic link in EMF. In support of the eosinophilia theory is the observation that EMF resembles a late stage of Loeffler's endocarditis (eosinophilic myocarditis) (<a class="graphic graphic_picture graphicRef71891" href="/z/d/graphic/71891.html" rel="external">picture 1</a>), a process known to result from sustained eosinophilia in patients with hypereosinophilic syndrome [<a href="#rid17">17,18</a>]. EMF and intraventricular thrombosis have also been observed following a variety of other eosinophilic syndromes including hypersensitivity myocarditis [<a href="#rid19">19</a>], parasitic infections [<a href="#rid17">17,18</a>], eosinophilic leukemia, sarcoma, carcinoma, and lymphoma [<a href="#rid20">20</a>], GM-CSF administration [<a href="#rid21">21</a>], and prolonged drug-induced eosinophilia. (See  <a class="medical medical_review" href="/z/d/html/2211.html" rel="external">"Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis", section on 'Cardiac disease'</a> and  <a class="medical medical_review" href="/z/d/html/4935.html" rel="external">"Treatment and prognosis of myocarditis in adults", section on 'Eosinophilic myocarditis'</a>.)</p><p>Despite the similarities between Loeffler’s endocarditis and EMF, serum and myocardial eosinophilia have not been consistently demonstrated in EMF. Although one study from Uganda found that 60 percent of patients with EMF had at least mild eosinophilia at the time of diagnosis compared with 10 percent of controls [<a href="#rid22">22</a>], in Kerala, India, most with EMF did not have active eosinophilia at the time of diagnosis [<a href="#rid23">23</a>]. Endomyocardial biopsies have not demonstrated eosinophilia in EMF, even in those suspected to have early disease [<a href="#rid24">24</a>]. It is possible that many with EMF have had significant eosinophilia at one time that is not detected by the time of presentation to medical care.</p><p class="headingAnchor" id="H15163013"><span class="h2">Infectious</span><span class="headingEndMark"> — </span>Several infections have been implicated in the pathophysiology of EMF, including toxoplasmosis [<a href="#rid25">25</a>], rheumatic fever [<a href="#rid26">26</a>], malaria [<a href="#rid27">27</a>], and helminthic parasites [<a href="#rid4">4,28</a>]. A consistent association with one organism, however, has not been demonstrated. For example, mice infected with plasmodium berghei develop EMF lesions [<a href="#rid29">29</a>], but a study of a series of 47 African children aged 5 to 15 years old with severe and complicated plasmodium falciparum infection produced insufficient evidence to link these two diseases [<a href="#rid30">30</a>]. Also opposing the infectious hypothesis is the observation that there are many tropical countries with similar burdens of malaria and filariasis as Uganda and Nigeria that do not have reported cases of EMF. (See  <a class="medical medical_review" href="/z/d/html/14003.html" rel="external">"Diagnostic testing for toxoplasmosis infection"</a> and  <a class="medical medical_review" href="/z/d/html/3177.html" rel="external">"Acute rheumatic fever: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5709.html" rel="external">"Malaria: Clinical manifestations and diagnosis in nonpregnant adults and children"</a> and  <a class="medical medical_review" href="/z/d/html/5707.html" rel="external">"Laboratory tools for diagnosis of malaria"</a> and  <a class="medical medical_review" href="/z/d/html/5675.html" rel="external">"Lymphatic filariasis: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H15163102"><span class="h2">Environmental exposure</span><span class="headingEndMark"> — </span>Given the regional differences in the frequency of EMF cases and the lack of unifying infectious etiology, the idea of a geochemical basis for EMF has gained popularity. Alimentation and toxicity have been proposed as causes of EMF [<a href="#rid2">2</a>]; proposed factors include malnutrition and a protein-poor diet (eg, leucine, valine, and tryptophan deficiency), magnesium deficiency, cassava toxicity, high vitamin D, serotonin, cerium and thorium, and traditional medicine plants.</p><p>Cassava is consumed extensively in some tropical African and Latin American countries. It contains linamarin, which may liberate cyanide in the gut. A low-protein diet diminishes the detoxification of cyanide, which may affect myocardial cell function. In animal models, cassava intake may induce interstitial fibrosis, intracellular vacuoles, and endocardial thickening in the absence of parasites or eosinophilia [<a href="#rid31">31,32</a>]. The relationship between cassava and EMF warrants further investigation [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H15163159"><span class="h2">Immunologic</span><span class="headingEndMark"> — </span>The presence of anti-myosin autoantibodies has been demonstrated in EMF; however, these antibodies can be detected in other forms of heart disease such as Dressler’s syndrome, rheumatic heart disease, and in patients with post-transplant rejection [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H15163186"><span class="h2">Genetic</span><span class="headingEndMark"> — </span>A familial link has been identified in many studies; however, it is not known whether this is due to an environmental or genetic cause or both [<a href="#rid9">9,35</a>]. </p><p class="headingAnchor" id="H15163271"><span class="h1">CLINICAL PHASES AND MANIFESTATIONS</span><span class="headingEndMark"> — </span>Three phases have been identified based upon clinical and pathologic manifestations: an initial phase of active recurrent inflammation, followed by a transient progressive form, and an advanced chronic fibrotic phase with restrictive cardiomyopathy [<a href="#rid2">2</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>The initial form appears as a febrile illness, with pancarditis, eosinophilia, dyspnea, and periorbital swelling [<a href="#rid2">2-4</a>]. There is no specific marker for EMF. Eosinophilia may be present, but its frequency is variable among reported series (ranging from 0 to 70 percent), perhaps in part due to delayed diagnosis of early EMF. The ECG is nonspecific, and echocardiography may show wall thickening (with or without echogenic endomyocardial infiltrates), reflecting inflammation and edema and pericardial effusion. Pathologic examination reveals myocardial interstitial edema, eosinophilic infiltration, subendocardial necrosis, and vasculitis. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The transient progressive form is characterized by chronic HF with edema, ascites, and cardiomegaly. Echocardiographic wall thickness returns to normal, but affected walls may show scars. Signs of restrictive physiology with chamber dilation (especially of the atria) may be seen. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The advanced form is characterized by chronic HF with ascites, edema, and cardiomegaly accompanied by typical echocardiographic findings, including apical fibrosis and restrictive ventricular filling pattern (see <a class="local">'Echocardiography'</a> below). The majority of patients have biventricular involvement, followed by the isolated right-sided form, and rarely the isolated left heart form. </p><p></p><p>The clinical manifestations of progressive and advanced EMF are largely related to the presence of right and/or left HF. Patients may report dyspnea on exertion, paroxysmal nocturnal dyspnea, orthopnea, lower extremity, and abdominal swelling. A history of a febrile illness with or without urticaria is occasionally obtained [<a href="#rid36">36</a>]. </p><p>In Africans with EMF in particular, there is often dramatic ascites, which may or may not be accompanied by other signs of right-sided HF, such as elevated jugular venous pressure and/or lower extremity edema [<a href="#rid37">37-40</a>]. The high prevalence of malnutrition and hypoalbuminemia may explain the predilection for ascites in this population. In one series, the ascitic fluid protein content was described as exudative in 35 of 47 patients with EMF, and the authors concluded that an inflammatory process might also be contributing [<a href="#rid38">38</a>]. The serum albumin to ascites gradient (which is a more accurate indicator of portal hypertension such as my result from HF) was not reported. (See  <a class="medical medical_review" href="/z/d/html/1261.html" rel="external">"Evaluation of adults with ascites", section on 'Determining the cause of the ascites'</a>.)</p><p>Patients with EMF also often have large pleural and pericardial effusions. Severe atrial enlargement leads to the appearance of cardiomegaly on chest radiography. Atrial fibrillation is common in end-stage disease and predicts a poor prognosis [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H15163383"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of EMF should be suspected in individuals in or from endemic areas with symptoms of HF (particularly ascites) and suggestive echocardiographic findings.</p><p>In high-resource as well as endemic countries, evaluation for cardiac involvement (including myocarditis or EMF) is indicated in patients with hypereosinophilia or abnormal eosinophils. Work-up includes obtaining a serum troponin and an echocardiogram. (See  <a class="medical medical_review" href="/z/d/html/2211.html" rel="external">"Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis"</a>.)</p><p>The diagnosis of EMF is made by summing points using the following severity scoring system with major and minor criteria [<a href="#rid9">9</a>]. Agreement by two independent experienced cardiologists is desirable. Definite EMF diagnosis includes two major criteria, or one major criterion with two minor criteria. Scores may range from 0 to 35; patients with eight or less are classified as mild, those with 8 to 15 as moderate, and those with 15 or more as severe. EMF is also classified as biventricular, right-sided, or left-sided ventricular involvement, according to clinical presentation and imaging findings. </p><p class="bulletIndent1"><span class="glyph">●</span>Major criteria</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Endomyocardial plaques &gt;2 mm in thickness</strong> – Two points</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thin (≤1 mm) endomyocardial patches affecting more than one ventricular wall</strong> – Three points</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Obliteration of the right or left ventricular apex</strong> – Four points</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thrombi or spontaneous contrast without severe ventricular dysfunction</strong> – Four points</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Retraction of the right ventricular apex (right ventricular apical notch)</strong> – Four points</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Atrioventricular-valve dysfunction due to adhesion of the valvular apparatus to the ventricular wall</strong> – One to four points (more points assigned for more severe atrioventricular regurgitation)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Minor criteria</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thin endomyocardial patches localized to one ventricular wall</strong> – One point</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Restrictive flow pattern across mitral or tricuspid valves</strong> – Two points</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pulmonary-valve diastolic opening</strong> – Two points</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diffuse thickening of the anterior mitral leaflet</strong> – One point</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Enlarged atrium with normal-sized ventricle</strong> – Two points</p><p class="bulletIndent2"><span class="glyph">•</span><strong>M-movement of the interventricular septum and flat posterior wall</strong> – One point (see <a class="local">'Echocardiography'</a> below)</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Enhanced density of the moderator or other intraventricular bands</strong> – One point</p><p></p><p>Cardiac imaging findings are nearly identical for EMF seen in the tropics and non-tropical EMF.  </p><p class="headingAnchor" id="H15163391"><span class="h2">Echocardiography</span><span class="headingEndMark"> — </span>Although clinically similar to Loffler’s endocarditis, the diagnosis of endomyocardial fibrosis (EMF) should be reserved for patients from endemic regions without a clearly identified cause for sustained eosinophilia with the classic echocardiography features listed below [<a href="#rid6">6,42,43</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Apical fibrosis of the right ventricle (RV), left ventricle (LV), or both ventricles<strong> </strong>(<a class="graphic graphic_diagnosticimage graphicRef60129" href="/z/d/graphic/60129.html" rel="external">image 2</a> and <a class="graphic graphic_figure graphicRef59830" href="/z/d/graphic/59830.html" rel="external">figure 2</a>)<strong>.</strong></p><p class="bulletIndent1"><span class="glyph">●</span>Tethering the atrioventricular (AV) valve papillary muscles, leading to mitral and/or tricuspid regurgitation (<a class="graphic graphic_diagnosticimage graphicRef53361" href="/z/d/graphic/53361.html" rel="external">image 1</a>).<strong> </strong></p><p class="bulletIndent1"><span class="glyph">●</span>Giant atrial enlargement (<a class="graphic graphic_diagnosticimage graphicRef53361" href="/z/d/graphic/53361.html" rel="external">image 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Restrictive filling pattern on Doppler recordings of mitral valve inflow (<a class="graphic graphic_waveform graphicRef68541" href="/z/d/graphic/68541.html" rel="external">waveform 1</a>).<strong> </strong></p><p></p><p>In addition, apical thrombi are often present (<a class="graphic graphic_diagnosticimage graphicRef80830" href="/z/d/graphic/80830.html" rel="external">image 3</a>). When available, administration of microbubble echocardiographic contrast agent should be considered to identify and define the extent of apical thrombus (see  <a class="medical medical_review" href="/z/d/html/5313.html" rel="external">"Contrast echocardiography: Clinical applications"</a>). In EMF, the apex maintains inward systolic contractile motion that may help to differentiate EMF from other causes of apical thrombi associated with an akinetic or dyskinetic apex such as myocardial infarction or Chagas disease [<a href="#rid6">6</a>] (<a class="graphic graphic_figure graphicRef59830" href="/z/d/graphic/59830.html" rel="external">figure 2</a>). </p><p>On M-mode echocardiography, a characteristic interventricular septal M-movement or pattern may be identified; this septal bounce results from rapid anterior movement in early diastole, which creates a characteristic M-movement or pattern [<a href="#rid44">44</a>]. </p><p>An echocardiographic screening study in Mozambique included echocardiographic criteria for the diagnosis and staging of EMF [<a href="#rid9">9</a>]. As the natural history of EMF is not well defined, these criteria will likely aid in defining the stages of this disease and in determining the clinical significance of early EMF.</p><p class="headingAnchor" id="H15163473"><span class="h2">Cardiac catheterization</span><span class="headingEndMark"> — </span>Cardiac catheterization is not required for the diagnosis of EMF. However, on hemodynamic studies, a restrictive pattern is observed with diastolic dip and plateau pressure tracings. Depending on the ventricle involved, mitral and tricuspid regurgitation may be demonstrated. Ventricular angiography reveals apical obliteration of the affected ventricle (<a class="graphic graphic_diagnosticimage graphicRef60129" href="/z/d/graphic/60129.html" rel="external">image 2</a>) [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H15163497"><span class="h2">Cardiovascular magnetic resonance imaging</span><span class="headingEndMark"> — </span>Cardiovascular magnetic resonance (CMR) imaging with contrast demonstrates myocardial fibrosis (<a class="graphic graphic_diagnosticimage graphicRef80830" href="/z/d/graphic/80830.html" rel="external">image 3</a>) [<a href="#rid46">46,47</a>]. In a series of 36 patients with EMF, patients with fibrous tissue deposition identified by late gadolinium enhancement cardiac magnetic resonance imaging indexed to body surface area (FT/BSA) of &gt;19 mL/m<sup>2</sup>, had increased mortality rate, worse New York Heart Association functional class, and increased likelihood of surgery [<a href="#rid48">48</a>]. However, the utility of this information in addition to echocardiography is unclear, and this modality is generally unavailable in areas with the highest burden of disease. In early disease where there is suspicion for active inflammation, CMR may be useful in identifying patients who may benefit from steroid therapy. (See  <a class="medical medical_review" href="/z/d/html/5314.html" rel="external">"Clinical utility of cardiovascular magnetic resonance imaging", section on 'Late gadolinium enhancement'</a>.) </p><p class="headingAnchor" id="H2038072922"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>At the early active inflammation stage, differentiation with other acute febrile illness is difficult, except by the presence of hypereosinophilia. Other causes of acute myocarditis should be excluded. In the chronic fibrotic stage various imaging modalities, as mentioned before, are almost identical between Loeffler's and Davies's diseases. In the presence of ascites, other causes of liver disease or portal hypertension should be ruled out. As a restrictive cardiomyopathy, EMF should be differentiated from other cardiomyopathies as sarcoidosis, amyloidosis, infiltrative process, and of unknown origin. </p><p class="headingAnchor" id="H7"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The natural history of EMF is not fully defined. Most present to medical care with end-stage disease and suffer an annual mortality as high as 25 percent despite medical treatment [<a href="#rid41">41,49</a>]. </p><p class="headingAnchor" id="H514351837"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Limited data are available to guide management. Surgical management has led to long-term survival in some patients with EMF [<a href="#rid7">7</a>]; however, this option is unavailable in regions with a high disease burden.</p><p class="headingAnchor" id="H8"><span class="h2">Medical therapy</span><span class="headingEndMark"> — </span>Available literature is limited to case series that do not fully define treatment regimens [<a href="#rid41">41,49</a>]. A general approach can be extrapolated from the treatment of patients with HF due to restrictive diastolic dysfunction from other causes. (See  <a class="medical medical_review" href="/z/d/html/3461.html" rel="external">"Treatment and prognosis of heart failure with preserved ejection fraction"</a> and  <a class="medical medical_review" href="/z/d/html/4943.html" rel="external">"Definition and classification of the cardiomyopathies", section on 'Restrictive cardiomyopathy'</a>.)</p><p>Diuretics and rate control for atrial fibrillation are currently the mainstays of therapy.</p><p>Pleural, pericardial, or ascitic fluid removal may alleviate symptoms, but these often reaccumulate. In patients with suspected acute carditis, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> may be of benefit. (See  <a class="medical medical_review" href="/z/d/html/4935.html" rel="external">"Treatment and prognosis of myocarditis in adults", section on 'Eosinophilic myocarditis'</a>.) </p><p>Standard recommendations for anticoagulation apply to patients with atrial fibrillation (see  <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants"</a>). However, appropriate use and management of anticoagulants are generally difficult in EMF endemic regions. </p><p class="headingAnchor" id="H9"><span class="h2">Surgery</span><span class="headingEndMark"> — </span>Endomyocardial resection with valve replacement or repair of the mitral valve has gained prominence at many centers, especially in subjects in advanced HF [<a href="#rid7">7,48,50,51</a>]. Tricuspid valve replacement has had poor results. Immediate postoperative mortality is high, ranging from 15 to 30 percent, but surgery offers the possibility of long-term survival [<a href="#rid7">7,51</a>]. Published series have been small, controlled data are lacking, and overall experience is limited. Questions remain about the appropriate timing, perioperative mortality, and long-term prognosis (<a class="graphic graphic_diagnosticimage graphicRef53361" href="/z/d/graphic/53361.html" rel="external">image 1</a> and <a class="graphic graphic_diagnosticimage graphicRef60677" href="/z/d/graphic/60677.html" rel="external">image 4</a>). Cardiac surgery is not routinely available in areas with high EMF prevalence. </p><p>A surgical series of 83 patients with EMF from Brazil with mean age 31 years (range 4 to 59) and New York Heart Association functional class III to IV symptoms had a survival probability of 55 percent at 17 years [<a href="#rid7">7</a>]. There were 15 late deaths (six unrelated to EMF) during mean 7.7-year follow-up. Four patients were reoperated on for recurrent fibrosis, five patients were reoperated on for native or prosthetic valve disease, and in six patients, EMF appeared in the other ventricle.</p><p class="headingAnchor" id="H29222886"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Endomyocardial fibrosis (EMF) is a restrictive cardiomyopathy observed in the tropics usually at the end-stage of the disease. It may be indistinguishable from Loeffler’s endocarditis, observed in temperate climates.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The pathogenesis remains unknown; however, eosinophilia may play a role.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Echocardiography may show uni- or bilateral ventricular apex obliteration with severely dilated atria and a restrictive filling pattern.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The prognosis is poor, with a mortality estimated at 25 percent per year. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Limited data suggest that surgical treatment with endomyocardial resection and valve replacement may be beneficial in patients with advanced apical obliteration and severe heart failure symptoms; however, this option is largely unavailable where the disease is present.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sliwa K, Damasceno A, Mayosi BM. Epidemiology and etiology of cardiomyopathy in Africa. Circulation 2005; 112:3577.</a></li><li><a class="nounderline abstract_t">Grimaldi A, Mocumbi AO, Freers J, et al. Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. Circulation 2016; 133:2503.</a></li><li><a class="nounderline abstract_t">Connor DH, Somers K, Hutt MS, et al. Endomyocardial fibrosis in Uganda (Davies' disease). 1. An epidemiologic, clinical, and pathologic study. Am Heart J 1967; 74:687.</a></li><li><a class="nounderline abstract_t">Andy JJ, Ogunowo PO, Akpan NA, et al. Helminth associated hypereosinophilia and tropical endomyocardial fibrosis (EMF) in Nigeria. Acta Trop 1998; 69:127.</a></li><li><a class="nounderline abstract_t">Valiathan MS, Balakrishnan KG, Sankarkumar R, Kartha CC. Surgical treatment of endomyocardial fibrosis. Ann Thorac Surg 1987; 43:68.</a></li><li><a class="nounderline abstract_t">Acquatella H, Schiller NB, Puigbó JJ, et al. Value of two-dimensional echocardiography in endomyocardial disease with and without eosinophilia. A clinical and pathologic study. Circulation 1983; 67:1219.</a></li><li><a class="nounderline abstract_t">Moraes F, Lapa C, Hazin S, et al. Surgery for endomyocardial fibrosis revisited. Eur J Cardiothorac Surg 1999; 15:309.</a></li><li><a class="nounderline abstract_t">BALL JD, WILLIAMS AW, DAVIES JN. Endomyocardial fibrosis. Lancet 1954; 266:1049.</a></li><li><a class="nounderline abstract_t">Mocumbi AO, Ferreira MB, Sidi D, Yacoub MH. A population study of endomyocardial fibrosis in a rural area of Mozambique. N Engl J Med 2008; 359:43.</a></li><li><a class="nounderline abstract_t">Kutty VR, Abraham S, Kartha CC. Geographical distribution of endomyocardial fibrosis in south Kerala. Int J Epidemiol 1996; 25:1202.</a></li><li><a class="nounderline abstract_t">Radhakumary C, Kumari TV, Kartha CC. Endomyocardial fibrosis is associated with selective deposition of type I collagen. Indian Heart J 2001; 53:486.</a></li><li><a class="nounderline abstract_t">Rutakingirwa M, Ziegler JL, Newton R, Freers J. Poverty and eosinophilia are risk factors for endomyocardial fibrosis (EMF) in Uganda. Trop Med Int Health 1999; 4:229.</a></li><li><a class="nounderline abstract_t">Falase AO. Endomyocardial fibrosis in Africa. Postgrad Med J 1983; 59:170.</a></li><li><a class="nounderline abstract_t">Connor DH, Somers K, Hutt MS, et al. Endomyocardial fibrosis in Uganda (Davies' disease). II. An epidemiologic, clinical, and pathologic study. Am Heart J 1968; 75:107.</a></li><li><a class="nounderline abstract_t">Mocumbi AO, Yacoub MH, Yokohama H, Ferreira MB. Right ventricular endomyocardial fibrosis. Cardiovasc Pathol 2009; 18:64.</a></li><li><a class="nounderline abstract_t">Chopra P, Narula J, Talwar KK, et al. Histomorphologic characteristics of endomyocardial fibrosis: an endomyocardial biopsy study. Hum Pathol 1990; 21:613.</a></li><li><a class="nounderline abstract_t">Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994; 83:2759.</a></li><li class="breakAll">Spry CJF. A Comprehensive Review and Guide to the Scientific and Medical Literature, Oxford Medical Publications, Oxford 1988.</li><li><a class="nounderline abstract_t">Kendell KR, Day JD, Hruban RH, et al. Intimate association of eosinophils to collagen bundles in eosinophilic myocarditis and ranitidine-induced hypersensitivity myocarditis. Arch Pathol Lab Med 1995; 119:1154.</a></li><li><a class="nounderline abstract_t">Monsuez JJ, de Kerviler E, Barboteu M, et al. Non-Hodgkin's lymphoma related eosinophilic endomyocardial disease. Eur Heart J 1994; 15:1423.</a></li><li><a class="nounderline abstract_t">Donhuijsen K, Haedicke C, Hattenberger S, et al. Granulocyte-macrophage colony-stimulating factor-related eosinophilia and Loeffler's endocarditis. Blood 1992; 79:2798.</a></li><li><a class="nounderline abstract_t">Freers J, Masembe V, Schmauz R, Mayanja-Kizza H. Endomyocardial fibrosis syndrome in Uganda. Lancet 2000; 355:1994.</a></li><li><a class="nounderline abstract_t">Valiathan SM, Kartha CC. Endomyocardial fibrosis--the possible connexion with myocardial levels of magnesium and cerium. Int J Cardiol 1990; 28:1.</a></li><li><a class="nounderline abstract_t">Patel AK, Ziegler JL, D'Arbela PG, Somers K. Familial cases of endomyocardial fibrosis in Uganda. Br Med J 1971; 4:331.</a></li><li><a class="nounderline abstract_t">Ijaola O, Falase AO. Distribution of antibodies against Coxsackie B viruses, arboviruses and Toxoplasma gondii among patients with endomyocardial fibrosis (EMF) compared with normal subjects from EMF endemic and non-endemic zones of Nigeria. Afr J Med Med Sci 1990; 19:93.</a></li><li><a class="nounderline abstract_t">Shaper AG. Endomyocardial fibrosis and rheumatic heart-disease. Lancet 1966; 1:639.</a></li><li><a class="nounderline abstract_t">Eling WM, Jerusalem CR, Heinen-Borries UJ, et al. Is malaria involved in the pathogenesis of tropical endomyocardial fibrosis? Acta Leiden 1988; 57:47.</a></li><li><a class="nounderline abstract_t">Ive FA, Willis AJ, Ikeme AC, Brockington IF. Endomyocardial fibrosis and filariasis. Q J Med 1967; 36:495.</a></li><li><a class="nounderline abstract_t">Eling WM, Jerusalem CR, Heinen-Borries U. Role of macrophages in the pathogenesis of endomyocardial fibrosis in murine malaria. Trans R Soc Trop Med Hyg 1984; 78:43.</a></li><li><a class="nounderline abstract_t">Mocumbi AO, Songane M, Salomão C, et al. Lack of evidence of myocardial damage in children with Plasmodium falciparum severe and complicated malaria from an endemic area for endomyocardial fibrosis. J Trop Pediatr 2011; 57:312.</a></li><li><a class="nounderline abstract_t">Sezi CL. Effects of cassava diet on Cercopithecus aethiops livers: a case for cassava as the cause of both tropical splenomegaly syndrome (TSS) and endomyocardial fibrosis (EMF). East Afr Med J 1996; 73:S24.</a></li><li><a class="nounderline abstract_t">Sezi CL. Effect of protein deficient cassava diet on Cercopithecus aethiops hearts and its possible role in the aetiology and pathogenesis of endomyocardial fibrosis in man. East Afr Med J 1996; 73:S11.</a></li><li><a class="nounderline abstract_t">Chelo D, Nguefack F, Mbassi Awa HD, Kingue S. Endomyocardial fibrosis in Sub Saharan Africa: The geographical origin, socioeconomic status, and dietary habits of cases reported in Yaounde, Cameroon. Ann Pediatr Cardiol 2015; 8:202.</a></li><li><a class="nounderline abstract_t">Mocumbi AO, Latif N, Yacoub MH. Presence of circulating anti-myosin antibodies in endomyocardial fibrosis. PLoS Negl Trop Dis 2010; 4:e661.</a></li><li><a class="nounderline abstract_t">Lowenthal MN. Endomyocardial fibrosis: familial and other cases from northern Zambia. Med J Zambia 1978; 12:2.</a></li><li class="breakAll">Freers J, Hakim J, Myanja-Kizza H, Parry E. The Heart. In: Principles of Medicine in Africa, Parry E, Godfrey R, Mabey D, Gill G (Eds), Cambridge University Press, Cambridge 2004. p.837.</li><li><a class="nounderline abstract_t">Freers J, Mayanja-Kizza H, Rutakingirwa M, Gerwing E. Endomyocardial fibrosis: why is there striking ascites with little or no peripheral oedema? Lancet 1996; 347:197.</a></li><li><a class="nounderline abstract_t">Barretto AC, Mady C, Oliveira SA, et al. Clinical meaning of ascites in patients with endomyocardial fibrosis. Arq Bras Cardiol 2002; 78:196.</a></li><li><a class="nounderline abstract_t">Marijon E, Hausse AO, Ferreira B. Typical clinical aspect of endomyocardial fibrosis. Int J Cardiol 2006; 112:259.</a></li><li><a class="nounderline abstract_t">Guimarães AC, Esteves JP, Filho AS, Macedo V. Clinical aspects of endomyocardial fibrosis in Bahia, Brazil. Am Heart J 1971; 81:7.</a></li><li><a class="nounderline abstract_t">Barretto AC, Mady C, Nussbacher A, et al. Atrial fibrillation in endomyocardial fibrosis is a marker of worse prognosis. Int J Cardiol 1998; 67:19.</a></li><li><a class="nounderline abstract_t">Berensztein CS, Piñeiro D, Marcotegui M, et al. Usefulness of echocardiography and doppler echocardiography in endomyocardial fibrosis. J Am Soc Echocardiogr 2000; 13:385.</a></li><li><a class="nounderline abstract_t">Hassan WM, Fawzy ME, Al Helaly S, et al. Pitfalls in diagnosis and clinical, echocardiographic, and hemodynamic findings in endomyocardial fibrosis: a 25-year experience. Chest 2005; 128:3985.</a></li><li><a class="nounderline abstract_t">Beaton A, Mocumbi AO. Diagnosis and Management of Endomyocardial Fibrosis. Cardiol Clin 2017; 35:87.</a></li><li><a class="nounderline abstract_t">Barretto AC, da Luz PL, de Oliveira SA, et al. Determinants of survival in endomyocardial fibrosis. Circulation 1989; 80:I177.</a></li><li><a class="nounderline abstract_t">Qureshi N, Amin F, Chatterjee D, et al. MR imaging of endomyocardial fibrosis (EMF). Int J Cardiol 2011; 149:e36.</a></li><li><a class="nounderline abstract_t">Smedema JP, Winckels SK, Snoep G, et al. Tropical endomyocardial fibrosis (Davies' disease): case report demonstrating the role of magnetic resonance imaging. Int J Cardiovasc Imaging 2004; 20:517.</a></li><li><a class="nounderline abstract_t">Salemi VM, Rochitte CE, Shiozaki AA, et al. Late gadolinium enhancement magnetic resonance imaging in the diagnosis and prognosis of endomyocardial fibrosis patients. Circ Cardiovasc Imaging 2011; 4:304.</a></li><li class="breakAll">Wynne J, Braunwald E.. The Cardiomyopathies. In: Braunwald's Heart Disease, Zipes DP, Libby P, Bonow RO, Braunwald E (Eds), Elsevier Saunders, Philadeplhia 2005. p.1659.</li><li><a class="nounderline abstract_t">Schneider U, Jenni R, Turina J, et al. Long-term follow up of patients with endomyocardial fibrosis: effects of surgery. Heart 1998; 79:362.</a></li><li><a class="nounderline abstract_t">Mocumbi AO, Yacoub S, Yacoub MH. Neglected tropical cardiomyopathies: II. Endomyocardial fibrosis: myocardial disease. Heart 2008; 94:384.</a></li></ol></div><div id="topicVersionRevision">Topic 4927 Version 14.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16330699" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Epidemiology and etiology of cardiomyopathy in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27297343" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4861733" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Endomyocardial fibrosis in Uganda (Davies' disease). 1. An epidemiologic, clinical, and pathologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9588233" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Helminth associated hypereosinophilia and tropical endomyocardial fibrosis (EMF) in Nigeria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3800484" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Surgical treatment of endomyocardial fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6851016" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Value of two-dimensional echocardiography in endomyocardial disease with and without eosinophilia. A clinical and pathologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10333028" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Surgery for endomyocardial fibrosis revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13164323" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Endomyocardial fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18596273" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A population study of endomyocardial fibrosis in a rural area of Mozambique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9027525" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Geographical distribution of endomyocardial fibrosis in south Kerala.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11759940" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Endomyocardial fibrosis is associated with selective deposition of type I collagen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10223220" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Poverty and eosinophilia are risk factors for endomyocardial fibrosis (EMF) in Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6844202" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Endomyocardial fibrosis in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4229457" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Endomyocardial fibrosis in Uganda (Davies' disease). II. An epidemiologic, clinical, and pathologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18402830" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Right ventricular endomyocardial fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2351390" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Histomorphologic characteristics of endomyocardial fibrosis: an endomyocardial biopsy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8180373" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The idiopathic hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8180373" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The idiopathic hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7503665" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Intimate association of eosinophils to collagen bundles in eosinophilic myocarditis and ranitidine-induced hypersensitivity myocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7821324" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Non-Hodgkin's lymphoma related eosinophilic endomyocardial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1586727" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Granulocyte-macrophage colony-stimulating factor-related eosinophilia and Loeffler's endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10859061" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Endomyocardial fibrosis syndrome in Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2194985" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Endomyocardial fibrosis--the possible connexion with myocardial levels of magnesium and cerium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5124410" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Familial cases of endomyocardial fibrosis in Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2165348" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Distribution of antibodies against Coxsackie B viruses, arboviruses and Toxoplasma gondii among patients with endomyocardial fibrosis (EMF) compared with normal subjects from EMF endemic and non-endemic zones of Nigeria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4159678" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Endomyocardial fibrosis and rheumatic heart-disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3072819" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Is malaria involved in the pathogenesis of tropical endomyocardial fibrosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6077228" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Endomyocardial fibrosis and filariasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6710575" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Role of macrophages in the pathogenesis of endomyocardial fibrosis in murine malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19948781" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Lack of evidence of myocardial damage in children with Plasmodium falciparum severe and complicated malaria from an endemic area for endomyocardial fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8756024" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effects of cassava diet on Cercopithecus aethiops livers: a case for cassava as the cause of both tropical splenomegaly syndrome (TSS) and endomyocardial fibrosis (EMF).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8756020" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effect of protein deficient cassava diet on Cercopithecus aethiops hearts and its possible role in the aetiology and pathogenesis of endomyocardial fibrosis in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26556966" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Endomyocardial fibrosis in Sub Saharan Africa: The geographical origin, socioeconomic status, and dietary habits of cases reported in Yaounde, Cameroon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20422043" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Presence of circulating anti-myosin antibodies in endomyocardial fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/757895" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Endomyocardial fibrosis: familial and other cases from northern Zambia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/757895" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Endomyocardial fibrosis: familial and other cases from northern Zambia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8544570" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Endomyocardial fibrosis: why is there striking ascites with little or no peripheral oedema?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11887195" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Clinical meaning of ascites in patients with endomyocardial fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16257072" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Typical clinical aspect of endomyocardial fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4992925" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Clinical aspects of endomyocardial fibrosis in Bahia, Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9880197" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Atrial fibrillation in endomyocardial fibrosis is a marker of worse prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10804436" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Usefulness of echocardiography and doppler echocardiography in endomyocardial fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16354870" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pitfalls in diagnosis and clinical, echocardiographic, and hemodynamic findings in endomyocardial fibrosis: a 25-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27886792" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Diagnosis and Management of Endomyocardial Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2766524" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Determinants of survival in endomyocardial fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19410309" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : MR imaging of endomyocardial fibrosis (EMF).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15856635" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Tropical endomyocardial fibrosis (Davies' disease): case report demonstrating the role of magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21415124" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Late gadolinium enhancement magnetic resonance imaging in the diagnosis and prognosis of endomyocardial fibrosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21415124" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Late gadolinium enhancement magnetic resonance imaging in the diagnosis and prognosis of endomyocardial fibrosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9616343" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Long-term follow up of patients with endomyocardial fibrosis: effects of surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18276824" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Neglected tropical cardiomyopathies: II. Endomyocardial fibrosis: myocardial disease.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
